# GHK-Cu Dosage in Preclinical Research: Routes, Concentrations, and Stability

> GHK-Cu dosage ranges across published research: 1-10 nM in vitro, 15 mg/kg intranasal in murine models, topical nano-carriers in human trials. No validated human systemic protocol exists.

## How GHK-Cu has been dosed in the published research

GHK-Cu has been studied across a range of delivery routes and concentration ranges. Understanding the dosage context — what was administered to which species by which route — is essential for reading the literature accurately. The research on GHK-Cu spans in vitro cell culture (nanomolar), murine intraperitoneal and intranasal dosing (µg/mL/day and mg/kg), oral gavage (mg/kg), and topical human clinical applications. These are distinct experimental contexts, and dose ranges do not translate between them.

No established human dosing protocol exists for injectable or intranasal GHK-Cu. Human clinical data is limited to topical applications [5, 7, 17]. All descriptions below are research-context summaries of published study designs, not clinical guidance.

## In vitro: nanomolar dose-response studies

Most of the foundational mechanistic GHK-Cu research uses nanomolar concentrations applied directly to human or rodent cell cultures:

Wound healing fibroblast models: 1–10 nM GHK-Cu in irradiated human dermal fibroblasts induced VEGF and bFGF expression; collagen content of wound chambers in rat models reached 538% of control values at day 22 [4].

Collagen and elastin expression: a dose-response range of 0.01, 1, and 100 nM was tested in human adult dermal fibroblasts. Collagen and elastin production increased across the range; MMP-1 and MMP-2 were upregulated at 0.01 nM while TIMP-1 was elevated at all concentrations [5].

Stem cell and keratinocyte activation: GHK-Cu at nanomolar concentrations (1–10 nM) increased epidermal stem cell markers (integrins, p63) in keratinocytes and enhanced mesenchymal stem cell secretion of VEGF and bFGF [20].

Cell death protection: GHK (free tripeptide, without copper) prevented copper- and zinc-induced protein aggregation and CNS cell death at 0–1000 µM in BV2 microglia, primary cerebellar neurons, and astrocytes — effective as a metal-sequestration agent rather than a copper deliverer in this context [11].

## Murine and rodent dosage: systemic and intranasal studies

**Pulmonary fibrosis model (intraperitoneal)**: GHK peptide at 2.6, 26, and 260 µg/mL/day IP in C57BL/6 mice showed dose-dependent inhibition of bleomycin-induced pulmonary fibrosis. The 260 µg/mL/day group showed the strongest reduction in collagen deposition, TGF-beta1 expression, and EMT markers [8].

**Alzheimer's model (intranasal)**: 5xFAD transgenic mice received GHK-Cu at 15 mg/kg intranasal 3x weekly for 12 weeks. Spontaneous alternation improved, escape latency decreased, and amyloid plaque burden in frontal cortex and hippocampus was significantly reduced [9].

**Aging cognitive model (intranasal)**: naturally aged C57BL/6 mice received GHK-Cu at 15 mg/kg intranasal daily for 8 weeks. Spatial learning and working memory improved in both sexes; axonal damage marker (neurofilament light-chain) decreased; neuroinflammation (MCP-1) was reduced in the frontal cortex of female mice. Male response emerged at 4 weeks; female response at 8 weeks [10].

**Ulcerative colitis model (oral)**: GHK-Cu at 20 mg/kg oral gavage in DSS-induced colitis mice (BALB/c) reduced disease activity index, preserved mucosal architecture, increased tight junction proteins ZO-1 and Occludin, and modulated SIRT1/STAT3 signaling [12].

**Anti-aging behavioral (systemic)**: aged C57BL/6 mice treated with GHK at 15 mg/kg showed improved learning versus saline controls; ROS reduction was also measured in oxidative-stress cell models at this dose range [13].

Copper homeostasis safety consideration: published mouse studies used copper loads estimated well below the ~35 mg/kg copper-ion toxicity threshold. GHK-Cu delivers copper in the chelated, biologically regulated form — not as a free ion — which limits toxicity risk relative to equivalent doses of copper salts [19].

## Topical formulations: clinical trial concentrations

**Wrinkle reduction RCT**: a nano-carrier formulation of GHK-Cu applied twice daily to 40 female volunteers (ages 40–65) for 8 weeks produced a 55.8% reduction in wrinkle volume (p<0.001) and 32.8% reduction in wrinkle depth (p=0.012) versus control serum; and 31.6% wrinkle volume reduction versus a Matrixyl 3000 comparator (p=0.004) [5]. The nano-carrier concentration was not separately published.

**Androgenetic alopecia RCT**: ALAVAX formulation containing 5-aminolevulinic acid and GHK peptide at either 50 mg/mL or 100 mg/mL was applied topically over 6 months to 45 male subjects with androgenetic alopecia (Norwood-Hamilton II–V). Hair count increased by 71.5 (50 mg/mL group) and 52.6 (100 mg/mL group) versus 9.6 for placebo [7]. The formulation is a combination product; the contribution of GHK specifically to the total effect has not been isolated.

**Post-CO2 laser resurfacing**: topical copper tripeptide complex applied post-procedure in 13 patients showed significantly higher patient satisfaction in the GHK-Cu group (p=0.04) vs control; objective erythema resolution did not reach statistical significance between groups [17].

**Formulation stability**: GHK-Cu is stable in buffered aqueous solution at pH 5.5–7. Destabilization occurs with strong AHAs/BHAs at low pH and high-concentration ascorbic acid (which competes for copper coordination). Palmitoylation and nano-carrier encapsulation have been studied as strategies to improve both stability and skin permeability [15].

## Pharmacokinetics and half-life: what the research shows

Validated human pharmacokinetic data for GHK-Cu is not available in the peer-reviewed literature as of 2025. Rodent data suggests plasma clearance after subcutaneous injection at 1–3 mg is rapid, estimated at 25–35 minutes post-injection — but no published human PK study exists to confirm whether this rodent clearance estimate translates to humans [15].

Topical application produces negligible systemic absorption at clinical formulation concentrations but sustains dermal presence through the epidermal-dermal compartment. The nano-carrier delivery approach studied in the 2016 clinical trial was specifically designed to address the compound's inherent hydrophilicity and limited passive skin permeability [5, 15].

The endogenous circulating level of GHK in human plasma — approximately 200 ng/mL at age 20, declining to ~80 ng/mL at age 60 — provides a natural reference range for what tissues experience biologically [13]. Whether topical or systemic GHK-Cu administration raises circulating GHK above these endogenous levels has not been characterized in humans.

---

A medical-desk index of the peer-reviewed GHK-Cu record — thirty-plus studies indexed, copper-biology cited at the source, no clinic behind the reference shelf.